Provided by Tiger Trade Technology Pte. Ltd.

Alnylam Pharmaceuticals

236.22
+6.923.02%
Post-market: 236.480.2586+0.11%19:58 EDT
Volume:1.91M
Turnover:449.27M
Market Cap:31.52B
PE:42.04
High:238.97
Open:228.88
Low:228.34
Close:229.30
52wk High:495.55
52wk Low:197.81
Shares:133.43M
Float Shares:133.16M
Volume Ratio:1.16
T/O Rate:1.43%
Dividend:- -
Dividend Rate:- -
EPS(TTM):5.62
EPS(LYR):2.33
ROE:96.55%
ROA:12.34%
PB:23.28
PE(LYR):101.38

Loading ...

Alnylam And Inceptive Form Strategic AI Collaboration To Accelerate Discovery Of RNAi Therapeutics

Reuters
·
Jun 04

Alnylam Commits Up to $2B to AI-Driven Therapeutic Innovation -- Company Talk

Dow Jones
·
Jun 04

Alnylam Collaboration Aims to Accelerate Timelines For Drug Discovery -- Company Talk

Dow Jones
·
Jun 04

Alnylam, Inceptive form strategic AI collaboration

TIPRANKS
·
Jun 04

Alnylam partners with Inceptive in AI-driven RNAi drug discovery deal worth up to $2 billion

Reuters
·
Jun 04

Alnylam Pharmaceuticals - Co and Inceptive Collaboration Valued at up to $2 Bln With $30 Mln Upfront

THOMSON REUTERS
·
Jun 04

Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of Rnai Therapeutics

THOMSON REUTERS
·
Jun 04

Alnylam director David E.I. Pyott disposes of USD 1.14 million in common shares

Reuters
·
Jun 04

Alnylam files Form 3 for director Benjamin Cravatt

Reuters
·
Jun 04

How Investors May Respond To Alnylam Pharmaceuticals (ALNY) Adding Scientific Depth Amid RNAi Pipeline Scrutiny

Simply Wall St.
·
May 29

Alnylam shareholders back executive pay in advisory vote at annual meeting

Reuters
·
May 28

Analysts’ Top Healthcare Picks: Alnylam Pharma (ALNY), Insulet (PODD)

TIPRANKS
·
May 27

Assessing Alnylam Pharmaceuticals (ALNY) Valuation After Mixed Share Performance And Strong AMVUTTRA Uptake

Simply Wall St.
·
May 23

J.P. Morgan Reaffirms Their Buy Rating on Alnylam Pharma (ALNY)

TIPRANKS
·
May 20

U.S. RESEARCH ROUNDUP-CAVA Group, Eagle Materials, Vertiv

Reuters
·
May 20

Alnylam Pharmaceuticals Inc : JP Morgan Resumes Coverage With Overweight Rating; Price Target $420

THOMSON REUTERS
·
May 20

Alnylam Pharmaceuticals Initiated at Buy by Citigroup

Dow Jones
·
May 19

Alnylam publishes 2025 corporate responsibility report

Reuters
·
May 19

Alnylam Pharmaceuticals Inc : Citigroup Initiates Coverage With Buy Rating; Target Price $380

THOMSON REUTERS
·
May 19

U.S. RESEARCH ROUNDUP-Costco Wholesale, HCA Healthcare, Micron Technology

Reuters
·
May 19